3.45
-0.2(-5.48%)
Currency In USD
| Previous Close | 3.65 |
| Open | 3.61 |
| Day High | 3.64 |
| Day Low | 3.32 |
| 52-Week High | 3.8 |
| 52-Week Low | 1.01 |
| Volume | 1.41M |
| Average Volume | 2.12M |
| Market Cap | 978.81M |
| PE | -8.02 |
| EPS | -0.43 |
| Moving Average 50 Days | 2.8 |
| Moving Average 200 Days | 1.84 |
| Change | -0.2 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $197.93 as of December 23, 2025 at a share price of $3.45. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $841.46 as of December 23, 2025 at a share price of $3.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca to Present at the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 2:08 PM GMT
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE
Erasca to Present at Upcoming Conferences in November
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to